(AOF) – As of December 31, 2021, Nanobiotix estimated to have approximately € 83.9 million in cash, compared to € 119.2 million as of December 31, 2020. Thanks to operational efficiency adjustments undertaken during the second half of 2021 , Nanobiotix has been able to extend its financial visibility and now expects its cash flow and investments as at December 31, 2021, excluding the possible payment of any milestone payments for its benefit in the context of its collaborations. will finance its operational plans until the second quarter of 2023.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an unprecedented amount of credits (7 billion euros): 1.5 billion for university hospital research, 2 billion for investment in health via bpi France , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenses reimbursed by Medicare will be 2.4%, which should generate at least 0.5% growth in laboratory turnover,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the actual benefit is sufficient.